TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04201314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InnoSlim®
Description: Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study: NCT01344044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.

Intervention type: DEVICE
Group type: OTHER
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Study: NCT00733772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 30 grams/day of flaxseed for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health lifestyle counseling
Description: Health lifestyle counseling accroding to AHA reccommendation
Study: NCT04201314

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: InnoSlim®
Description: Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study: NCT00791544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral intake
Study: NCT03197181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
Study: NCT00733772

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health lifestyle counseling
Description: Health lifestyle counseling accroding to AHA reccommendation
Study: NCT02857192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Study: NCT04261959

Intervention type: OTHER
Intervention: myoActivation
Description: myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.

Intervention type: OTHER
Intervention: myoActivation
Description: myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.

Intervention type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).

Intervention type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
Study: NCT00712218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Lymphadenectomy (LNE)
Description: No lymphadenectomy is performed in patients of the control group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (LNE)
Description: Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
Study: NCT04376957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool
Description: This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care consisting of standard counselling
Description: Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
Study: NCT04421859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EyeCU Mobile Application
Description: Augmented reality glaucoma education mobile phone application
Study: NCT04173195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk
Description: A short and brief conversation based on the principles of clinical hypnosis.
Study: NCT03346265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment A combined exercise program and gait training with sensory cues
Description: Treatment A consisted in a combined exercise program of 40 min duration RMP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment B Conventional physiotherapy
Description: Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
Study: NCT02725112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
Study: NCT02688088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT01839019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-102
Description: Single dose escalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ODM-102
Description: Single dose escalation
Study: NCT05393414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid based protocol
Description: Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid sparing protocol
Description: Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
Study: NCT00366028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Organization Model
Description: The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
Study: NCT04577118

Intervention type: DEVICE
Group type: OTHER
Intervention: iotaSOFT Insertion System
Description: Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
Study: NCT00366028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data Feedback Model
Description: The research team will periodically interview the facilities and provide them with reported hand hygiene data.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data Feedback Model
Description: The research team will periodically interview the facilities and provide them with reported hand hygiene data.
Study: NCT01246479

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: blood draw at Month 12, Month 24 and Month 36.
Study: NCT03727490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repair
Description: The subscapularis will be repaired.
Study: NCT00876005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen by mask
Description: Postoperatively, an aerosol face mask is used to deliver oxygen at 80%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen by mask
Description: Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
Study: NCT03156738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: Subjects will receive a single IV dose of MT-2990
Study: NCT03727490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: No repair will be performed
Study: NCT00782145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Study: NCT01246479

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IC51 has given in the parent study IC51-322
Description: No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
Study: NCT00782145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: informational intervention
Study: NCT00564330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid
Study: NCT03172065

Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline
Description: intravenous flluid
Study: NCT00564330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid
Study: NCT03309527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-aid Cognitive Behavior Therapy
Description: e-aid Cognitive Behavior Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-aid Sleep Hygiene Education
Description: e-aid Sleep Hygiene Education
Study: NCT00782145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Study: NCT03147625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHAPE Intervention
Description: SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
Study: NCT02918253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: targeted focal HDR brachytherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-gland HDR Brachytherapy
Description: Control/Standard of Care
Study: NCT03331835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid esters
Description: Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
Study: NCT00782145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Study: NCT01977508

Intervention type: DEVICE
Intervention: ePTFE vascular access grafts
Study: NCT03761381

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCTA) Imaging
Description: Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
Study: NCT00451646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOF lipid and Intralipid
Description: 1-2 g, 5-7 days, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid and Intralipid
Description: 1-2 g, 5-7 days, 28 days
Study: NCT04169945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic instrumentation
Description: Full mouth root surface debridement
Study: NCT03172065

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: anaesthetic adjuvants and pain killer medication.
Study: NCT01952444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ETI-204
Description: A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
Study: NCT00889889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02581462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT alone
Description: Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLOT + Herceptin/Pertuzumab
Description: Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43.
Study: NCT02246192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus pilonidal excision+ PRGF
Description: open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus pilonidal excision and standard cares
Description: sinus pilonidal excision and postoperative standard care with povidone daily
Study: NCT00828399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine 30g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole protein
Description: Oral whole protein 30 g/day
Study: NCT02128243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 de-escalation
Description: S-1 30 mg/m² bid d1-14 q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy by Investigator's choice
Description: Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT
Study: NCT02267304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of sodium chloride (0,9%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of sodium chloride (0,9%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of sodium chloride (0,9%)
Study: NCT04169945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Description: Full mouth root surface debridement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air flow PLUS
Study: NCT02267304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine 0,05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine 0,05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine 0,05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 10mg
Study: NCT00892203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01838785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ AV-133
Study: NCT02120963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered physical therapy intervention program
Description: Comparison of person-centered physical therapy and control group